Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Summary

This is an open, single-arm, clinical study to evaluate efficacy and safety of anti CD7 CAR-T cell in the treatment of relapsed and refractory CD7+ T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma

Timeline

Start

2021-01-27

Primary completion

2023-01-31

Completion

2023-03-31

Publications

• Cao XY, Zhang JP, Wei ZJ, Lu Y, Zhao YL, Xiong M, Zhou JR, Wang Y, Yang JF, Zhang X, Li J, Lu P. Long-Term Outcomes of Second Allogeneic Transplantation Following CD7 CAR-T in Remission for T-Cell Acute Lymphoblastic Leukemia or Lymphoma. Transplant Cell Ther. 2026 Jun 1:S2666-6367(26)00445-8. doi: 10.1016/j.jtct.2026.05.045. Online ahead of print.

Drugs

Indications